Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery.
Cenix BioScience GmbH (Dresden) announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latter¹s efforts in the discovery and validation of novel therapeutic drug targets.
Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing with high content phenotypic analyses in cultured human cells. The initial project will involve a HT-RNAi screen using an assay strategy co-designed with AstraZeneca scientists to discover and validate novel oncology targets. Cenix will adapt and implement multi-parametric microscopy-based assays using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes. Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
Other news from the department business & finance
